Last reviewed · How we verify
Striatal dopamine transporter visualization using single photon emission computed tomography — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Datscan | IOFLUPANE I 123 | Ge Hlthcare Inc | Radioactive Diagnostic Agent [EPC] | Sodium-dependent dopamine transporter | 2011-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Ge Hlthcare Inc · 1 drug in Striatal dopamine transporter visualization using single photon emission computed tomography
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Striatal dopamine transporter visualization using single photon emission computed tomography:
- Striatal dopamine transporter visualization using single photon emission computed tomography treatment updates — RSS
- Striatal dopamine transporter visualization using single photon emission computed tomography treatment updates — Atom
- Striatal dopamine transporter visualization using single photon emission computed tomography treatment updates — JSON
Cite this brief
Drug Landscape (2026). Striatal dopamine transporter visualization using single photon emission computed tomography — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/striatal-dopamine-transporter-visualization-using-single-photon-emission-computed-tomography. Accessed 2026-06-10.
Related
- Striatal dopamine transporter visualization using single photon emission computed tomography full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing